Attorneys

Philip E. Hansen, Ph.D.

Philip E. Hansen, Ph.D.

Partner

Office: Albany | 518-452-5600 linkedin

philip.hansen@nullhrfmlaw.com | vCard

Philip E. Hansen brings 16 years of experience as a research chemist in the pharmaceutical industry and 28 years as a patent agent to the prosecution of patent applications. Dr. Hansen has spent his entire career in the field of organic medicinal chemistry. His undergraduate thesis at Princeton was “Synthesis of 6,7-Disubstituted Pteridines” under E.C Taylor. Although Phil’s thesis work – relating to folate antagonists – resulted in no drugs, Professor Taylor’s work on folate antimetabolites resulted in ALIMTA®. His PhD thesis at Cornell under Professor Hans Muxfeldt was titled “The Total Synthesis of Aureomycin and Tetracycline”. For 16 years he was a Senior Research Chemist at Sterling Drug (since absorbed into Sanofi Aventis), where he worked on bronchodilators, and antibiotics (aminoglycosides and beta lactams), finishing up in peptide analgesics and antihypertensive agents. While at Sterling, he was recruited into the Patent Department, where he was a Patent Agent.

At the start of his career at HRFM, Phil worked on any chemical invention that came in the door, from polymers to integrated circuit fabrication, but for the past fifteen years his practice has been largely limited to patent drafting, prosecution and counseling in his area of expertise–small molecule therapeutics, including processes and formulations relating thereto. Phil’s practice is worldwide. Representative clients include: Sunovion Pharmaceuticals, Mt. Sinai School of Medicine, The Rockefeller University, Memorial Sloan Kettering Cancer Center, and Stanford University.

Phil is fluent in German with a working knowledge of French.

Speed and the Patent Office: A Contradiction?, The Daily Record IP Frontiers, March 15, 2011

Inventorship: A cautionary tale, The Daily Record IP Frontiers, January 19, 2010

Co-Authored:  A Day (or more) In the Life of a Patent; Term Adjustments can be Contentious, The Business Review New Frontiers, December 3, 2004

The Law Requires More Diligence with Pending Patent Application, The Business Review, December 1, 2000

The American Inventors Protection Act of 1999, May 16, 2000

  • Ph.D. in Chemistry, Cornell University, 1970
  • A.B. in Chemistry, Princeton University, 1966
  • NIH predoctoral fellow
  • Eastern New York Intellectual Property Law Association (President, 1991-93)
  • American Intellectual Property Law Association (AIPLA)
  • American Chemical Society (ACS)
  • U.S. Patent and Trademark Office
  • Overview

    Philip E. Hansen brings 16 years of experience as a research chemist in the pharmaceutical industry and 28 years as a patent agent to the prosecution of patent applications. Dr. Hansen has spent his entire career in the field of organic medicinal chemistry. His undergraduate thesis at Princeton was “Synthesis of 6,7-Disubstituted Pteridines” under E.C Taylor. Although Phil’s thesis work – relating to folate antagonists – resulted in no drugs, Professor Taylor’s work on folate antimetabolites resulted in ALIMTA®. His PhD thesis at Cornell under Professor Hans Muxfeldt was titled “The Total Synthesis of Aureomycin and Tetracycline”. For 16 years he was a Senior Research Chemist at Sterling Drug (since absorbed into Sanofi Aventis), where he worked on bronchodilators, and antibiotics (aminoglycosides and beta lactams), finishing up in peptide analgesics and antihypertensive agents. While at Sterling, he was recruited into the Patent Department, where he was a Patent Agent.

    At the start of his career at HRFM, Phil worked on any chemical invention that came in the door, from polymers to integrated circuit fabrication, but for the past fifteen years his practice has been largely limited to patent drafting, prosecution and counseling in his area of expertise–small molecule therapeutics, including processes and formulations relating thereto. Phil’s practice is worldwide. Representative clients include: Sunovion Pharmaceuticals, Mt. Sinai School of Medicine, The Rockefeller University, Memorial Sloan Kettering Cancer Center, and Stanford University.

    Phil is fluent in German with a working knowledge of French.

  • Publications

    Speed and the Patent Office: A Contradiction?, The Daily Record IP Frontiers, March 15, 2011

    Inventorship: A cautionary tale, The Daily Record IP Frontiers, January 19, 2010

    Co-Authored:  A Day (or more) In the Life of a Patent; Term Adjustments can be Contentious, The Business Review New Frontiers, December 3, 2004

    The Law Requires More Diligence with Pending Patent Application, The Business Review, December 1, 2000

    The American Inventors Protection Act of 1999, May 16, 2000

  • Education
    • Ph.D. in Chemistry, Cornell University, 1970
    • A.B. in Chemistry, Princeton University, 1966
  • Recognitions
    • NIH predoctoral fellow
  • Memberships
    • Eastern New York Intellectual Property Law Association (President, 1991-93)
    • American Intellectual Property Law Association (AIPLA)
    • American Chemical Society (ACS)
  • Admissions
    • U.S. Patent and Trademark Office